Microarray Technology
This issue contains three manuscripts showing application of microarray technology to toxicologic pathology. The cover illustration is meant to draw attention to the currently fuzzy interface between genomic microarray technology and our discipline. With subsequent applications and time this interface will undoubtedly become more sharply focused. For now, we are on the threshold of embracing this latest tool, always hopeful that it will ultimately represent a tangible contribution to toxicologic pathology. In considering what promise this new technology holds for us, we may hear raging enthusiasm from the proponents of molecular pathology and surmise that this is the philosopher's stone that will resolve all our difficulties at predicting target organ specific adverse effects with a few short laboratory bench experiments. One is reminded of the zealous promises proposed for transgenic animal models to supplant conventional rodent bioassays, for oncogene analysis to sort the chemical specific induction of cancer responses from the spontaneous cancers seen in our rodent models, and for in vitro test batteries to correctly categorize agents as carcinogens or non-carcinogens. As we enter the threshold of microarray technology, we consider what promises it holds. That this new microarray technology will positively impact many scientific disciplines including diagnostics, drug discovery, compound screening, and basic research in cancer biology, developmental biology, cell signaling, and gene function is a given. But we must also appreciate that simply grinding up a tissue and extracting the RNA for a microarray run is not the preferred approach, especially for pleomorphic responses that characterize response to xenobiotics. Rather, an accurate morphologic diagnosis and selection of the appropriate subsample will remain essential to appropriate utilization of this new technology. As with many new technologies, microarrays are costly and establishing a competent laboratory operation with a bioinformatics infrastructure is time consuming. We hear the buzz phrase "high throughput" and must bear in mind that this refers to many genes and EST's and not to many individual samples, at least not yet. Some of us may find it hard to envision that a microarray constellation of up-and down-regulated genes seen after a 3-day or 2-week exposure will provide a reliable fingerprint that predicts a particular chronic toxicity or potential carcinogenic response for a given tissue, yet alone for the multiple tissues in the body that are potential targets. After all, we still struggle with predicting chronic effects from acute and prechronic morphologic findings. Still, I sense we will get caught up in the contagious enthusiasm for new technologies such as microarrays, proteomics, and metabonomics because deep down we appreciate that they represent additional tools that we can keep in our tool box to use when the time is appropriate and the questions they can answer are relevant. We must also ask "What is the role of the toxicologic pathologist in promising new technologies?" Resistance is futile and counterproductive. The mutual benefit of working closely with the molecular biologists will help keep this and future emerging technologies relevant and focused on our most important questions.
